LY6E

Summary

LY6E (lymphocyte antigen 6 family member E, HGNC:6727) is a protein-coding gene on chromosome 8q24.3, encoding Lymphocyte antigen 6E (Q16553). GPI-anchored cell surface protein that regulates T-lymphocytes proliferation, differentiation, and activation.

This gene belongs to the human Ly6 gene family and encodes a glycosylphosphatidyl-inositol (GPI)-anchored cell surface protein. The protein plays an important role in T cell physiology, oncogenesis and immunological regulation. The protein is also involved in modulation of viral infection by coronaviruses, SARS-CoV, MERS-CoV and SARS-CoV-2.

Source: NCBI Gene 4061 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 38 total
• Druggable target: yes
• MANE Select transcript: NM_002346

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:6727
Approved symbol	LY6E
Name	lymphocyte antigen 6 family member E
Location	8q24.3
Locus type	gene with protein product
Status	Approved
Aliases	TSA-1, RIG-E, SCA-2
Ensembl gene	ENSG00000160932
Ensembl biotype	protein_coding
OMIM	601384
Entrez	4061

Gene structure

Transcript identifiers

Ensembl transcripts: 50 — 49 protein_coding, 1 protein_coding_CDS_not_defined

ENST00000292494, ENST00000429120, ENST00000517503, ENST00000519546, ENST00000519611, ENST00000519615, ENST00000520466, ENST00000520531, ENST00000521003, ENST00000521182, ENST00000521699, ENST00000522024, ENST00000522528, ENST00000522971, ENST00000523847, ENST00000891132, ENST00000891133, ENST00000891134, ENST00000891135, ENST00000891136, ENST00000891137, ENST00000891138, ENST00000891139, ENST00000891140, ENST00000891141, ENST00000891142, ENST00000891143, ENST00000891144, ENST00000891145, ENST00000891146, ENST00000891147, ENST00000891148, ENST00000891149, ENST00000891150, ENST00000891151, ENST00000891152, ENST00000891153, ENST00000891154, ENST00000891155, ENST00000891156, ENST00000891157, ENST00000891158, ENST00000891159, ENST00000891160, ENST00000891161, ENST00000891162, ENST00000891163, ENST00000964930, ENST00000964931, ENST00000964932

RefSeq mRNA: 2 — MANE Select: NM_002346 NM_001127213, NM_002346

CCDS: CCDS6394

Canonical transcript exons

ENST00000292494 — 4 exons

Exon	Start	End
ENSE00001141198	143020883	143020991
ENSE00002101953	143018529	143018586
ENSE00003469314	143021314	143021433
ENSE00003603930	143021566	143022409

Expression profiles

Bgee: expression breadth ubiquitous, 145 present calls, max score 99.16.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 181.7059 / max 2217.2817, expressed in 1817 samples.

FANTOM5 promoters (5 alternative TSS)

Promoter ID	TPM avg	Samples expressed
91372	146.4860	1808
91371	32.1694	1798
91375	1.6558	889
91374	1.2860	718
91370	0.1087	36

Top tissues by expression

145 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
right lobe of liver	UBERON:0001114	99.16	gold quality
granulocyte	CL:0000094	99.04	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	98.95	gold quality
liver	UBERON:0002107	98.83	gold quality
stromal cell of endometrium	CL:0002255	98.81	gold quality
placenta	UBERON:0001987	98.78	gold quality
right ovary	UBERON:0002118	98.70	gold quality
right lung	UBERON:0002167	98.66	gold quality
upper lobe of left lung	UBERON:0008952	98.66	gold quality
Ammon’s horn	UBERON:0001954	98.63	gold quality
right frontal lobe	UBERON:0002810	98.63	gold quality
left adrenal gland	UBERON:0001234	98.61	gold quality
endocervix	UBERON:0000458	98.60	gold quality
left adrenal gland cortex	UBERON:0035825	98.58	gold quality
apex of heart	UBERON:0002098	98.55	gold quality
right adrenal gland cortex	UBERON:0035827	98.52	gold quality
nucleus accumbens	UBERON:0001882	98.51	gold quality
frontal cortex	UBERON:0001870	98.50	gold quality
putamen	UBERON:0001874	98.50	gold quality
ectocervix	UBERON:0012249	98.50	gold quality
right adrenal gland	UBERON:0001233	98.49	gold quality
right uterine tube	UBERON:0001302	98.46	gold quality
prefrontal cortex	UBERON:0000451	98.45	gold quality
right hemisphere of cerebellum	UBERON:0014890	98.44	gold quality
spleen	UBERON:0002106	98.42	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	98.41	gold quality
left uterine tube	UBERON:0001303	98.37	gold quality
caudate nucleus	UBERON:0001873	98.37	gold quality
superior frontal gyrus	UBERON:0002661	98.37	gold quality
cerebellar hemisphere	UBERON:0002245	98.34	gold quality

Single-cell (SCXA)

Detected in 13 experiment(s), a significant marker in 11.

Experiment	Marker?	Max mean expression
E-MTAB-10287	yes	108.44
E-HCAD-4	yes	58.47
E-GEOD-134144	yes	48.65
E-CURD-112	yes	22.63
E-HCAD-6	yes	20.51
E-ANND-3	yes	17.07
E-MTAB-9388	yes	14.40
E-MTAB-8142	yes	14.34
E-CURD-46	yes	13.62
E-HCAD-1	yes	12.17
E-MTAB-8498	yes	9.88
E-HCAD-13	no	1241.67
E-MTAB-10283	no	269.38

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): HMGA1, HMGA2, POU2F1, POU2F2

miRNA regulators (miRDB)

27 targeting LY6E, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4713-3P	100.00	65.92	505
HSA-MIR-3667-3P	99.99	67.17	1636
HSA-MIR-7111-5P	99.97	68.48	2062
HSA-MIR-4525	99.94	64.38	675
HSA-MIR-5010-5P	99.94	64.11	705
HSA-MIR-6721-5P	99.93	68.92	2981
HSA-MIR-4731-5P	99.89	67.23	2537
HSA-MIR-4492	99.87	68.25	3611
HSA-MIR-4447	99.85	67.81	2900
HSA-MIR-1200	99.71	70.42	1838
HSA-MIR-6715B-5P	99.64	69.63	1420
HSA-MIR-1827	99.63	68.57	3265
HSA-MIR-9851-3P	99.63	69.68	1110
HSA-MIR-4269	99.55	69.89	1373
HSA-MIR-486-3P	99.51	66.82	1901
HSA-MIR-6722-3P	99.45	67.62	1919
HSA-MIR-593-5P	99.34	69.50	965
HSA-MIR-4505	99.27	67.81	2678
HSA-MIR-5787	99.22	67.86	2628
HSA-MIR-1909-3P	99.03	66.56	1662
HSA-MIR-1304-5P	98.90	68.58	1054
HSA-MIR-4260	98.78	65.37	848
HSA-MIR-4742-3P	98.73	69.82	1803
HSA-MIR-1227-5P	98.65	65.32	1549
HSA-MIR-637	97.91	64.05	1517
HSA-MIR-3652	97.71	65.43	1890
HSA-MIR-4430	97.47	65.61	1813

Literature-anchored findings (GeneRIF, showing 18)

• Increased expression of the type I interferon-inducible gene, lymphocyte antigen 6 complex locus E, in peripheral blood cells is predictive of lupus activity in a large cohort of Chinese lupus patients. (PMID:18755862)
• Two SCA3 and one SCA2 cases have been identified which show autosomal dominant inheritance in Parkinson disease. (PMID:18990604)
• This study suggested that a mutation in SCA2 or SCA3/MJD may be one of the genetic causes of Parkinson’s disease in china. (PMID:19672991)
• the LY6E pathway in monocytes represents one of negative feedback mechanisms that counterbalance monocyte activation which may serve as a potential target for immune intervention. (PMID:25225669)
• LY6E level of gene expression may serve as good biomarkers for systemic lupus erythematosus diagnosis. (PMID:25344775)
• LY6E overexpression is associated with Breast Cancer Progression, Immune Escape, and Drug Resistance. (PMID:27197181)
• High LY6E expression is associated with breast cancer. (PMID:27589564)
• LY6E is a positive modulator of HIV-1 infection in primary human peripheral blood mononuclear cells, immortalized CD4+ T lymphoid cells, and macrophages. HIV Long Terminal Repeat-driven HIV-1 gene expression is also enhanced by LY6E, suggesting additional roles of LY6E in HIV-1 replication. (PMID:28130445)
• LY6E knockdown by targeted-siRNA inhibited gastric cancer cell survival and proliferation and induced G1-S cell cycle arrest and apoptosis in gastric cancer cells (PMID:29448250)
• LY6E belongs to a growing class of interferon-inducible factors that broadly enhance viral infectivity in an interferon-independent manner. (PMID:30190477)
• LY6E downregulates the cell surface receptor CD4. (PMID:30674630)
• A Phase I Study of DLYE5953A, an Anti-LY6E Antibody Covalently Linked to Monomethyl Auristatin E, in Patients with Refractory Solid Tumors. (PMID:32694157)
• Protein LY6E as a candidate for mediating transport of adeno-associated virus across the human blood-brain barrier. (PMID:32839948)
• alpha5-nAChR associated with Ly6E modulates cell migration via TGF-beta1/Smad signaling in non-small cell lung cancer. (PMID:34994389)
• Multidimension Analysis of the Prognostic Value, Immune Regulatory Function, and ceRNA Network of LY6E in Individuals with Colorectal Cancer. (PMID:35310607)
• LY6E protein facilitates adeno-associated virus crossing in a biomimetic chip model of the human blood-brain barrier. (PMID:36165190)
• Innovative biomarkers TCN2 and LY6E can significantly inhibit respiratory syncytial virus infection. (PMID:39313785)
• Exploring Molecular Drivers of PARPi Resistance in BRCA1-Deficient Ovarian Cancer: The Role of LY6E and Immunomodulation. (PMID:39408764)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Ly6e	ENSMUSG00000022587
rattus_norvegicus	Ly6e	ENSRNOG00000007091

Paralogs (2): PSCA (ENSG00000167653), GPIHBP1 (ENSG00000277494)

Protein

Protein identifiers

Lymphocyte antigen 6E — Q16553 (reviewed: Q16553)

Alternative names: Retinoic acid-induced gene E protein, Stem cell antigen 2, Thymic shared antigen 1

All UniProt accessions (6): Q16553, E5RGI6, E5RI33, E5RI58, E5RIQ1, E7EWF8

UniProt curated annotations — full annotation on UniProt →

Function. GPI-anchored cell surface protein that regulates T-lymphocytes proliferation, differentiation, and activation. Regulates the T-cell receptor (TCR) signaling by interacting with component CD3Z/CD247 at the plasma membrane, leading to CD3Z/CD247 phosphorylation modulation. Restricts the entry of human coronaviruses, including SARS-CoV, MERS-CoV and SARS-CoV-2, by interfering with spike protein-mediated membrane fusion. Also plays an essential role in placenta formation by acting as the main receptor for syncytin-A (SynA). Therefore, participates in the normal fusion of syncytiotrophoblast layer I (SynT-I) and in the proper morphogenesis of both fetal and maternal vasculatures within the placenta. May also act as a modulator of nicotinic acetylcholine receptors (nAChRs) activity. (Microbial infection) Promotes entry, likely through an enhanced virus-cell fusion process, of various viruses including HIV-1, West Nile virus, dengue virus and Zika virus. In contrast, the paramyxovirus PIV5, which enters at the plasma membrane, does not require LY6E. Mechanistically, adopts a microtubule-like organization upon viral infection and enhances viral uncoating after endosomal escape.

Subunit / interactions. Interacts with CHRNA4.

Subcellular location. Cell membrane.

Tissue specificity. Widely expressed, predominantly in liver, kidney, ovary, spleen and peripheral blood Leukocytes.

Induction. By retinoic acid; in promyelocytic leukemia NB4 and in myeloblast HL-60 cell lines. Activated by IFN-alpha in monocytic cell line U-937 and in peripheral blood monocyte cells.

RefSeq proteins (2): NP_001120685, NP_002337* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR016054	LY6_UPA_recep-like	Domain
IPR035076	Toxin/TOLIP	Domain
IPR045860	Snake_toxin-like_sf	Homologous_superfamily
IPR051110	Ly-6/neurotoxin-like_GPI-ap	Family

Pfam: PF00087

UniProt features (14 total): disulfide bond 5, mutagenesis site 3, signal peptide 1, chain 1, propeptide 1, domain 1, lipid moiety-binding region 1, glycosylation site 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q16553-F1	77.97	0.32

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 101

Disulfide bonds (5): 93–98, 23–48, 26–35, 41–71, 75–92

Glycosylation sites (1): 99

Mutagenesis-validated functional residues (3):

Position	Phenotype
36	complete loss of viral entry enhancement. abolishes inhibition of human coronaviruses entry.
57	about 50% loss of viral entry enhancement.
99	abolishes inhibition of human coronaviruses entry.

Function

Pathways and Gene Ontology

Reactome pathways

4 pathways

ID	Pathway
R-HSA-163125	Post-translational modification: synthesis of GPI-anchored proteins
R-HSA-9918485	Dengue Virus Attachment and Entry
R-HSA-392499	Metabolism of proteins
R-HSA-597592	Post-translational protein modification

MSigDB gene sets: 342 (showing top): GSE45365_NK_CELL_VS_CD8A_DC_UP, GSE18804_SPLEEN_MACROPHAGE_VS_COLON_TUMORAL_MACROPHAGE_UP, TONKS_TARGETS_OF_RUNX1_RUNX1T1_FUSION_MONOCYTE_UP, GOBP_RESPONSE_TO_NITROGEN_COMPOUND, YAGI_AML_WITH_INV_16_TRANSLOCATION, RODRIGUES_THYROID_CARCINOMA_POORLY_DIFFERENTIATED_UP, TGCTGCT_MIR15A_MIR16_MIR15B_MIR195_MIR424_MIR497, ENK_UV_RESPONSE_KERATINOCYTE_UP, MODULE_64, DACOSTA_UV_RESPONSE_VIA_ERCC3_UP, DARWICHE_SKIN_TUMOR_PROMOTER_UP, DARWICHE_PAPILLOMA_RISK_LOW_UP, GOBP_MODULATION_OF_PROCESS_OF_ANOTHER_ORGANISM, DARWICHE_PAPILLOMA_RISK_HIGH_UP, DARWICHE_SQUAMOUS_CELL_CARCINOMA_UP

GO Biological Process (3): cell surface receptor signaling pathway (GO:0007166), host-mediated suppression of symbiont invasion (GO:0046597), acetylcholine receptor signaling pathway (GO:0095500)

GO Molecular Function (3): acetylcholine receptor inhibitor activity (GO:0030550), acetylcholine receptor binding (GO:0033130), protein binding (GO:0005515)

GO Cellular Component (5): extracellular region (GO:0005576), plasma membrane (GO:0005886), synapse (GO:0045202), side of membrane (GO:0098552), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-3 pathways:

Category	Pathways
Post-translational protein modification	1
Dengue Virus Infection	1
Metabolism of proteins	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	3
acetylcholine receptor activity	2
membrane	2
signal transduction	1
innate immune response	1
host-mediated perturbation of symbiont process	1
postsynaptic signal transduction	1
cellular response to acetylcholine	1
signaling receptor inhibitor activity	1
acetylcholine receptor regulator activity	1
signaling receptor binding	1
binding	1
cell periphery	1
cell junction	1
leaflet of membrane bilayer	1

Protein interactions and networks

STRING

820 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
LY6E	PSCA	O43653	896
LY6E	IFI44L	Q53G44	710
LY6E	IFI6	P09912	686
LY6E	OAS1	P00973	673
LY6E	RSPH1	Q8WYR4	656
LY6E	MX1	P20591	607
LY6E	EPSTI1	Q96J88	592
LY6E	IFI44	Q8TCB0	582
LY6E	ISG15	P05161	580
LY6E	IFIT3	O14879	574
LY6E	CD59	P13987	561
LY6E	RSAD2	Q8WXG1	541
LY6E	IFITM3	Q01628	530
LY6E	IFIT1	P09914	524
LY6E	ERVW-1	Q9UQF0	522

IntAct

17 interactions, top by confidence:

A	B	Type	Score
TUSC5	LY6E	psi-mi:“MI:0915”(physical association)	0.560
TMEM19	LY6E	psi-mi:“MI:0915”(physical association)	0.560
LY6E	TMEM19	psi-mi:“MI:0915”(physical association)	0.560
LY6E	MFSD6	psi-mi:“MI:0915”(physical association)	0.560
LY6E	TMEM140	psi-mi:“MI:0915”(physical association)	0.560
rep	LY6E	psi-mi:“MI:0915”(physical association)	0.560
SLC22A1	FNDC10	psi-mi:“MI:0914”(association)	0.350
MFSD6	LY6E	psi-mi:“MI:0915”(physical association)	0.000
TMEM140	LY6E	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (22): CD247 (Affinity Capture-Western), LY6E (Affinity Capture-RNA), LY6E (Two-hybrid), LY6E (Two-hybrid), LY6E (Two-hybrid), TUSC5 (Two-hybrid), LY6E (Affinity Capture-RNA), LY6E (Two-hybrid), PHB (Affinity Capture-MS), HSP90AA1 (Affinity Capture-MS), HSP90AB1 (Affinity Capture-MS), EEF1G (Affinity Capture-MS), EIF4A1 (Affinity Capture-MS), PHB (Affinity Capture-Western), HSP90AA1 (Affinity Capture-Western)

ESM2 similar proteins: B3MFC2, B3NSF6, B4QBL6, B5A5T4, B5E022, D3ZTT2, D4A6L0, H3BQJ8, O43653, P12645, P19438, P22444, P23352, P46657, P49002, P50555, P57096, P58658, P58659, Q16553, Q1RMB5, Q28216, Q32LD3, Q505J3, Q568T5, Q5R510, Q5T848, Q66IA6, Q68US5, Q6UWL2, Q6UWN0, Q6UX15, Q6WN34, Q80XH4, Q86Y78, Q8BHE5, Q8BPP5, Q8BVP6, Q8C351, Q8C419

Diamond homologs: A0JNB3, O94772, P0DTL4, Q16553, Q4R5M8, Q63317, Q90986, Q9WU67, Q9WUC3, O43653, P0DP58, P57096, Q6UXB3, H3BJG9, P05533, P0CW02, P0CW03, P35460, P35461, Q64253, A0A346CIB2, Q9DD23, P55000, Q9Z0K7

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

38 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	19
Likely benign	2
Benign	3

Top pathogenic / likely-pathogenic (0)

SpliceAI

998 predictions. Top by Δscore:

Variant	Effect	Δscore
8:143020989:GAGGT:G	donor_loss	1.0000
8:143020991:GG:G	donor_loss	1.0000
8:143020992:G:GC	donor_loss	1.0000
8:143021309:C:A	acceptor_gain	1.0000
8:143021312:A:AG	acceptor_gain	1.0000
8:143021313:G:GA	acceptor_gain	1.0000
8:143021313:GCC:G	acceptor_gain	1.0000
8:143021313:GCCA:G	acceptor_gain	1.0000
8:143021431:TTG:T	donor_gain	1.0000
8:143021431:TTGGT:T	donor_loss	1.0000
8:143021432:TG:T	donor_gain	1.0000
8:143021432:TGG:T	donor_loss	1.0000
8:143021433:GG:G	donor_gain	1.0000
8:143021434:G:GA	donor_loss	1.0000
8:143021434:G:GG	donor_gain	1.0000
8:143021435:TGAG:T	donor_loss	1.0000
8:143018696:G:GT	donor_gain	0.9900
8:143018974:G:T	donor_gain	0.9900
8:143020881:A:AG	acceptor_gain	0.9900
8:143020882:G:GG	acceptor_gain	0.9900
8:143020882:G:T	acceptor_gain	0.9900
8:143020882:GA:G	acceptor_gain	0.9900
8:143020882:GAGCA:G	acceptor_gain	0.9900
8:143020987:GCGAG:G	donor_gain	0.9900
8:143021308:CCGCA:C	acceptor_loss	0.9900
8:143021309:CGCAG:C	acceptor_loss	0.9900
8:143021310:GCAG:G	acceptor_loss	0.9900
8:143021311:CAGC:C	acceptor_loss	0.9900
8:143021312:AG:A	acceptor_loss	0.9900
8:143021313:GC:G	acceptor_gain	0.9900

AlphaMissense

0 scored. Top likely-pathogenic:

dbSNP variants (sampled 300 via entrez): RS1000146671 (8:143016732 T>A,C), RS1001490623 (8:143017043 G>A), RS1002229761 (8:143018122 C>T), RS1002353141 (8:143020526 A>T), RS1002899792 (8:143017956 C>A,G), RS1003257317 (8:143020803 C>T), RS1003624371 (8:143019405 G>T), RS1003638150 (8:143019716 A>T), RS1004060446 (8:143019659 G>A,C), RS1004845844 (8:143022257 G>A), RS1005066347 (8:143016623 T>C), RS1005153751 (8:143020491 C>A), RS1005169132 (8:143016675 A>C), RS1005444732 (8:143017033 G>C), RS1006070634 (8:143017826 G>A)

Disease associations

OMIM: gene MIM:601384 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL4523584 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

60 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Tretinoin	decreases reaction, affects cotreatment, increases expression, increases reaction	6
sodium arsenite	decreases expression, affects cotreatment, increases abundance, increases expression	5
Cyclosporine	increases expression, decreases expression	3
Arsenic Trioxide	decreases reaction, increases expression, affects cotreatment	2
Estradiol	affects cotreatment, decreases expression, increases expression	2
Plant Extracts	decreases expression, affects cotreatment	2
Tobacco Smoke Pollution	decreases expression, increases expression	2
bisphenol A	increases expression	1
cobaltous chloride	decreases expression	1
2-bromopalmitate	increases expression, increases reaction	1
perfluorooctanoic acid	increases expression	1
manganese chloride	affects cotreatment, increases abundance, increases expression	1
potassium chromate(VI)	increases expression	1
hydroquinone	decreases expression	1
S-(1,2-dichlorovinyl)cysteine	affects response to substance, increases expression	1
tamibarotene	increases expression	1
di-n-butylphosphoric acid	affects expression	1
perfluorooctane sulfonic acid	increases expression	1
CGP 52608	affects binding, increases reaction	1
erucylphospho-N,N,N-trimethylpropylammonium	decreases expression	1
ICG 001	decreases expression	1
2,2’,4,4’-tetrabromodiphenyl ether	increases expression	1
jinfukang	affects cotreatment, increases expression	1
NSC 689534	affects binding, decreases expression	1
(+)-JQ1 compound	decreases expression	1
4-(4-((5-(4,5-dimethyl-2-nitrophenyl)-2-furanyl)methylene)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl)benzoic acid	decreases expression	1
Resveratrol	affects cotreatment, decreases expression	1
Temozolomide	decreases expression	1
Sunitinib	decreases expression	1
Acetaminophen	decreases expression	1

Cellosaurus cell lines

2 cell lines: 1 spontaneously immortalized cell line, 1 transformed cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_E6R4	Genomeditech CHO-K1 H_LY6E	Spontaneously immortalized cell line	Female
CVCL_E6UH	Genomeditech HEK-293 H_LY6E	Transformed cell line	Female

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.